Cingulate Inc.
A clinical-stage biopharma firm developing treatments for ADHD and anxiety.
CING | US
Overview
Corporate Details
- ISIN(s):
- US17248W1137 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 1901 W. 47TH PLACE, 66205 KANSAS CITY
- Website:
- https://www.cingulate.com/
- Sector:
- Manufacturing
Description
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The company utilizes its proprietary Precision Timed Release (PTR) drug delivery platform, a novel erosion-based technology, to create medications with a true once-daily dosing profile. This platform is designed to provide controlled drug release for entire active-day efficacy. Cingulate's pipeline includes product candidates CTX-1301 and CTX-1302 for the ADHD market, and CTX-2103 for the anxiety market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cingulate Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cingulate Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cingulate Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
